ATX-304
TO CONFIRM
Research compound; name matches ATX-304, a small-molecule AMPK activator in early clinical development, with item identity to be confirmed.
Evidence level. Little or no public data, or the exact identity is still being confirmed. About the badges
- Class
- TO CONFIRM
- Category
- Antioxidants & Specialty
- Type
- Single compound
- Development and regulatory status
- Status not confirmed
What researchers study
Name matches ATX-304, a small-molecule AMPK activator (not a peptide) described by its developer, Cambrian Bio, as in early clinical development; identity of the catalogue item is to be confirmed by Novatide.
Research areas
- AMPK-activation studies in fatty-liver mouse models
- Fatty-acid oxidation and lipid-synthesis pathway studies
- Early clinical metabolic-biomarker studies
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- rodent
In a mouse model of progressive fatty liver disease, ATX-304 lowered body fat mass and cholesterol and limited liver steatosis and fibrosis
- phase 1 trial
Company-reported phase 1b data in 23 adults with obesity and prediabetes showed lower triglycerides and liver fat by MRI, with minimal weight loss
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- AICARAnother AMPK activator studied in metabolic models
- MOTS-c (Human)AMPK-activating mitochondrial peptide studied in metabolic models
- SemaglutidePreclinical combination with ATX-304 was presented at ENDO 2025 by the developer
